Sagimet BiosciencesSTU:0O2 +1.66%10 EV-to-OCF is -8.55 as of Jun. 28, 2026. GuruFocus rates STU:0O2 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,417 Biotechnology companies, Sagimet Biosciences ranks better than 66.48% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Sagimet Biosciences's Enterprise Value is €291.75 Mil.
Sagimet Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was €-34.12 Mil. Therefore, Sagimet Biosciences's EV-to-OCF for today is -8.55.
The historical rank and industry rank for Sagimet Biosciences's EV-to-OCF or its related term are showing as below:
STU:0O2'
s EV-to-OCF Range Over the Past 10 Years
Min: -8.34 Med: -0.05 Max: 4.38
Current: -8.34
During the past 7 years, the highest EV-to-OCF of Sagimet Biosciences was 4.38. The lowest was -8.34. And the median was -0.05.
STU:0O2's EV-to-OCF is ranked better than 66.48% of 1417
companies
in the Biotechnology industry
Industry Median: -3.44
vs STU:0O2: -8.34
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sagimet Biosciences's PE Ratio (TTM) for today is calculated as:
Sagimet Biosciences's share price for today is €6.14.
Sagimet Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.151.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sagimet Biosciences EV-to-OCF Related Terms
Sagimet Biosciences EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Sagimet Biosciences's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Sagimet Biosciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sagimet Biosciences EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Sagimet Biosciences's EV-to-OCF falls into.
Sagimet Biosciences's current Enterprise Value is €291.75 Mil.
Sagimet Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-34.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sagimet Biosciences (STU:0O2) has a EV-to-OCF of -8.55 as of Jun. 28, 2026. According to the industry distribution chart, Sagimet Biosciences ranks #475 out of 1417 companies in the Biotechnology industry, placing it in the top 33.5%.
Is Sagimet Biosciences' EV-to-OCF too high?
Sagimet Biosciences' current EV-to-OCF is -8.55. Based on the distribution chart, Sagimet Biosciences ranks #475 out of 1417 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' EV-to-OCF compare to EDIT and AUTL?
According to the Biotechnology industry distribution chart, Sagimet Biosciences ranks #475 out of 1417 companies for EV-to-OCF. This puts Sagimet Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Sagimet Biosciences's current EV-to-OCF is -8.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current EV-to-OCF of -8.55. The current EV-to-OCF is -8.55. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current EV-to-OCF is -8.55 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score
Get the complete analysis for STU:0O2
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0O2 has been successfully added to your 
